In addition to this, a meta-analysis of nine clinical trials [65] shows a three times higher risk (OR 3.3 with CI 95%) of developing a malignancy in patients treated with anti-TNF-α vs. control; the risk is proportional to the dose administered. The gene discussed is TNF; the disease is cancer.